Helmut Forstbauer

2.6k total citations
53 papers, 412 citations indexed

About

Helmut Forstbauer is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Helmut Forstbauer has authored 53 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 29 papers in Cancer Research and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Helmut Forstbauer's work include Breast Cancer Treatment Studies (24 papers), Cancer Treatment and Pharmacology (17 papers) and Advanced Breast Cancer Therapies (15 papers). Helmut Forstbauer is often cited by papers focused on Breast Cancer Treatment Studies (24 papers), Cancer Treatment and Pharmacology (17 papers) and Advanced Breast Cancer Therapies (15 papers). Helmut Forstbauer collaborates with scholars based in Germany, Switzerland and United States. Helmut Forstbauer's co-authors include Hans‐Joachim Schmoll, Kim Jordan, C. Schlichting, Hendrik Kroening, O Kellner, Carolina Constantin, LG Mantovani, Georg Dietrich, Nadia Harbeck and K. E. Schneweis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Helmut Forstbauer

48 papers receiving 405 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helmut Forstbauer Germany	12	351	158	120	47	41	53	412
Gui‐Nan Lin China	8	254 0.7×	135 0.9×	97 0.8×	47 1.0×	32 0.8×	9	359
Franz J. Hilke Germany	10	114 0.3×	89 0.6×	68 0.6×	39 0.8×	62 1.5×	15	276
Monica Zuradelli Italy	11	186 0.5×	70 0.4×	87 0.7×	36 0.8×	55 1.3×	34	378
Sergi Clavé Spain	10	207 0.6×	117 0.7×	221 1.8×	20 0.4×	76 1.9×	26	365
Craig Vargo United States	8	172 0.5×	76 0.5×	102 0.8×	17 0.4×	114 2.8×	20	340
Gökçe Aşkan United States	10	193 0.5×	68 0.4×	105 0.9×	32 0.7×	64 1.6×	18	356
Luca Tondulli Italy	9	174 0.5×	63 0.4×	114 0.9×	33 0.7×	44 1.1×	14	285
Marco Russano Italy	10	239 0.7×	166 1.1×	139 1.2×	15 0.3×	124 3.0×	37	422
W. Brückl Germany	10	198 0.6×	45 0.3×	163 1.4×	53 1.1×	52 1.3×	27	329
Audrey Hennequin France	11	410 1.2×	81 0.5×	154 1.3×	19 0.4×	106 2.6×	34	561

Countries citing papers authored by Helmut Forstbauer

Since Specialization

Citations

This map shows the geographic impact of Helmut Forstbauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helmut Forstbauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helmut Forstbauer more than expected).

Fields of papers citing papers by Helmut Forstbauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helmut Forstbauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helmut Forstbauer. The network helps show where Helmut Forstbauer may publish in the future.

Co-authorship network of co-authors of Helmut Forstbauer

This figure shows the co-authorship network connecting the top 25 collaborators of Helmut Forstbauer. A scholar is included among the top collaborators of Helmut Forstbauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helmut Forstbauer. Helmut Forstbauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stintzing, Sebastian, Jan Wierecky, Helmut Forstbauer, et al.. (2023). Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study.. Journal of Clinical Oncology. 41(4_suppl). 34–34. 1 indexed citations

Kuon, Jonas, Stefan Wilop, Dirk Behringer, et al.. (2023). 1448P First-line nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study. Annals of Oncology. 34. S823–S824.

Gluz, Oleg, Christine zu Eulenburg, Ulrike Nitz, et al.. (2023). LBA24 Multiparametric prognostic score in early HR+/HER2- breast cancer: Impact of recurrence score, clinical-pathological factors, gene mutations and histology. Annals of Oncology. 34. S1262–S1263. 1 indexed citations

Prager, Gerald W., Jens Kisro, P. Stübs, et al.. (2023). PD-25 Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study. Annals of Oncology. 34. S11–S11. 1 indexed citations

Harbeck, Nadia, Raquel von Schumann, Ronald Kates, et al.. (2021). Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers. 13(19). 4884–4884. 10 indexed citations

Harbeck, Nadia, Oleg Gluz, Rachel Würstlein, et al.. (2021). The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. The Breast. 59. 58–66. 6 indexed citations

Harbeck, Nadia, Ulrike Nitz, Matthias Christgen, et al.. (2020). LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results. Annals of Oncology. 31. S1146–S1146. 5 indexed citations

Bekes, Inga, Martin Eichler, Susanne Singer, et al.. (2020). Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. Clinical Breast Cancer. 20(6). 439–447. 3 indexed citations

Gluz, Oleg, Ulrike Nitz, C Liedtke, et al.. (2018). Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology. 29. viii703–viii703. 4 indexed citations

10.

Janni, Wolfgang, Thomas W. P. Friedl, Tanja Fehm, et al.. (2018). Abstract GS1-06: Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study. Cancer Research. 78(4_Supplement). GS1–6. 9 indexed citations

11.

Ignatiadis, Michail, Saskia Litière, Françoise Rothé, et al.. (2018). Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. Annals of Oncology. 29(8). 1777–1783. 55 indexed citations

12.

Schmoll, Hans‐Joachim, Benjamin Garlipp, Christian Junghanß, et al.. (2017). FOLFOX/Bevacizumab +/− Irinotecan in advanced colorectal cancer (AIO) “CHARTA”: Final results and multivariate prognostic factor analysis. Annals of Oncology. 28. iii152–iii152. 1 indexed citations

13.

Schouten, Philip C., Karsten E. Weber, Valentina Nekljudova, et al.. (2017). BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. Breast Cancer Research and Treatment. 166(3). 775–785. 2 indexed citations

14.

Jueckstock, J, Brigitte Rack, Thomas W. P. Friedl, et al.. (2016). Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial. BMC Cancer. 16(1). 401–401. 14 indexed citations

15.

Schwentner, Lukas, Nadia Harbeck, Susanne Singer, et al.. (2016). Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial. The Breast. 27. 69–77. 9 indexed citations

16.

Schmoll, Hans‐Joachim, Benjamin Garlipp, Christian Junghanß, et al.. (2016). FOLFOX / Bevacizumab (Beva) +/- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA). Annals of Oncology. 27. vi560–vi560. 1 indexed citations

17.

Gluz, Oleg, Ulrike Nitz, Ronald Kates, et al.. (2014). Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.. Journal of Clinical Oncology. 32(15_suppl). 524–524. 2 indexed citations

18.

Loibl, Sibylle, Volkmar Mueller, Gϋnter von Minckwitz, et al.. (2010). Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Supportive Care in Cancer. 19(11). 1789–1795. 19 indexed citations

19.

Mey, Ulrich, Ingo G.H. Schmidt‐Wolf, Carsten Ziske, et al.. (2007). Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Supportive Care in Cancer. 15(7). 877–884. 24 indexed citations

20.

Schneweis, K. E., et al.. (1984). Pathogenesis of genital herpes simplex virus infection in mice. Medical Microbiology and Immunology. 173(4). 187–196. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact